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Abstract  
Previous estimates of whether long-term exposure to benzodiazepines increases dementia risk 
are conflicting and are compromised by the difficulty of controlling for confounders and by 
reverse causation. We investigated how estimates for the association between benzodiazepine 
use and later dementia incidence varied based on study design choices using a case-control 
study nested within the United Kingdom’s Clinical Practice Research Datalink. N=40,770 
dementia cases diagnosed between April 2006 and July 2015 were matched to 283,933 
controls on age, sex, available data history and deprivation. Benzodiazepines and Z-drug 
prescriptions were ascertained in a drug exposure period 4-20 years prior to dementia 
diagnosis.  Estimates varied with the inclusion of new or prevalent users, with the timing of 
covariate ascertainment, and with varying time between exposure and outcome.  There was 
no association between any new prescription of benzodiazepines and dementia (adjusted odds 
ratio 1.03; 95% confidence interval 1.00, 1.07), while among prevalent users and inverse 
association was observed (adjusted odds ratio 0.91; 95% confidence interval 0.87, 0.95), 
although this was likely induced by unintentional adjustment for colliders. By considering the 
choice of confounders and timing of exposure and covariate measurement, overall our 
findings are consistent with no causal effect of benzodiazepines or Z-drugs on dementia 
incidence. 
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Dementia prevention is a public health priority.  More than 152 million people are expected 
to be living with dementia by 2050, which is recognised as a leading cause of disability, and  
is the fifth most important cause of death with a global economic cost of US$1trillion (1, 2).  
There is no curative or disease modifying treatment for dementia, increasing the importance 
of identifying its risk factors (3). Several studies have suggested that long-term 
benzodiazepines use could increase dementia risk (4). If true this is an important opportunity 
to prevent dementia, as 9% of older US adults currently use benzodiazepines, with 31% of 
these being long-term users (5, 6). 
 
Benzodiazepines including diazepam (Valium), alprazolam (Xanax) and others are the most 
commonly prescribed sedatives, and are typically used for insomnia or anxiety. Despite years 
of guidance advising against long-term benzodiazepine use owing to side effects, addiction 
and tolerance (7), there has been no decline in their use in the past decade in the US (8-10), 
while a small decline in the UK has been accompanied by greater use of benzodiazepine-
related drugs including zopiclone, eszopiclone (e.g. Lunesta [Sunovion Pharmaceuticals Inc. 
Marlborough, MA]), zolpidem (e.g. Ambien [Sanofi-Aventis U.S. LLC, Bridgewater, NJ]), 
and zaleplon (e.g. Sonata [Wyeth Pharmaceuticals Inc., Philadelphia, PA]), collectively 
known as Z-drugs (11). 
 
Benzodiazepines and Z-drugs have dose-related effects on memory and other aspects of 
cognitive function (12, 13). However, no biological mechanism has been demonstrated to 
underlie any link to dementia incidence. While studies using insurance records and 
epidemiologic cohort studies have suggested increased risks of dementia with long-term 
benzodiazepine use (14-16), other recent studies have suggested no association (17, 18).  
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These conflicting results may reflect genuine differences across populations, or different 
study designs, availability and use of covariate data, or analysis parameters such as minimum 
time-lag between exposure and outcomes (19, 20). 
 
As it is not practical or ethical to randomize patients to benzodiazepine treatment to estimate 
harms, observational studies are central to addressing this important question.  Individual 
patient level datasets now exist that include detailed histories of benzodiazepine use going 
back years or decades, details of diagnoses and treatment for cognitive disorders and records 
of many possible confounding variables for this relationship.  However, several factors 
complicate any analysis.  Benzodiazepines are often initiated before records for a patient 
begin, precluding the use of the ‘new-user’ design (21).  This is particularly true for those 
with very long-term use, who may be most at risk (22). Second, the main indications for 
benzodiazepines, anxiety and sleep disturbance, are both risk factors for and prodromal 
symptoms of neurodegenerative disease that may occur many years before dementia 
diagnosis, necessitating a lag period to avoid protopathic bias (4).  Furthermore, dates 
associated with diagnoses in electronic health records may reflect the time of the underlying 
event. Together these make the theoretical identification of confounding from mediating or 
colliding variables, as is often suggested (23, 24), difficult.  This is important as valid causal 
inference relies on the correct identification and control for confounders (variables that are 
common causes of both the exposure and the outcome), but conditioning on mediators 
(variables on the causal pathway from exposure to outcome) or on colliders (common 
consequences of the exposure and the outcome) will introduce bias rather than reduce it (25). 
 
Case-control studies, where exposures within an ‘exposure period’ are compared between 
cases of a disease and matched controls, are often used for estimating the associations 
between multiple complex exposures and a single outcome.  Case-control studies are 
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particularly used when tackling rare adverse events, or those that may only become apparent 
after long-term exposures.  However, selection based on outcome rather than exposure status 
further complicates the ascertainment of confounders.  Clearly it is optimal to measure 
potential confounders at treatment initiation (20), but because cases and controls are not 
matched on exposure, the presence of treatment or time of treatment initiation will vary 
within a matched set.  Hence it is difficult to know when to optimally ascertain and encode 
covariates.  Measuring covariates recorded only up to the start of an exposure window 
(possibly years before exposure) risks missing confounders and omitted variable bias, while 
including covariates recorded during or after the exposure window (hence after the exposure) 
risks under-estimation through unintended adjustment for mediators or colliders (26).  
 
We conducted a case-control study nested within an electronic health record dataset as part of 
a wider project estimating the associations of drug use on dementia incidence (27), and have 
explored several of these issues.  We present estimates for the association between 
benzodiazepine and Z-drug prescription and dementia incidence, and explore how these 
depend on (a) the inclusion or exclusion of prevalent users, (b) the timing of covariate 
ascertainment, and (c) the minimum lag between treatment and dementia incidence.  Finally, 
we explore the role of specific covariates, and implications for the conduct and interpretation 
of future similar studies.  
 
 
 
METHODS 
 
The study has been approved by the Independent Scientific Advisory Committee for the 
Clinical Practice Research Datalink (CPRD) research (protocol number 15_056R) and was 
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registered on the ENCePP e-register of studies (register number EUPAS8705). This 
manuscript has been prepared according to the REporting of studies Conducted using 
Observational Routinely-collected Data guidelines (28). Code lists for the outcome and 
covariates are available on request. 
 
Study population and data 
CPRD consists of anonymised electronic health records of 17 million patients from 719 
general practices, and is representative of age, sex and ethnicity of the UK population (29).  
Available data include basic demographics and coded details of consultations, diagnoses, 
reported symptoms, drug prescriptions, referrals to specialist services, and laboratory test 
results.  
 
Selection of cases and controls 
All cases of dementia recorded in CPRD were indexed at the first mention of dementia as a 
diagnosis or symptom (see Web Table 1 for complete Read code list) or the first prescription 
of a dementia drug (memantine, donepezil, rivastigmine, galantamine, or tacrine) if it was 
followed by a dementia diagnosis code within twelve months.  
 
Cases were included in the current study if their index date occurred between April 2006 and 
July 2015 and the patient was aged between 65 and 99 years on that date. Cases were 
excluded if the date of diagnosis was unknown, they had less than 6 years of ‘Up-To-
Standard’ data history before the index date, or had any record of motor neuron disease, 
human immunodeficiency virus infection, acquired immune deficiency syndrome, multiple 
sclerosis, Down syndrome, or alcohol abuse. 
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For each case up to seven controls without dementia at the index date were randomly selected 
and matched on sex, year of birth (within 3 years), years of available Up-To-Standard data 
history, and index of multiple deprivation quintile. The index of multiple deprivation is a 
weighted sum of indicators of housing, employment, income, education, living environment 
and crime for each neighbourhood (30). We used incidence density sampling to select 
controls, hence cases could also be selected as controls up to the date of meeting case criteria. 
 
Exposure assessment 
We defined a drug exposure period (DEP) for each case/control group as the period starting 
after 1 year of Up-To-Standard data recorded, and at most 20 years before the index date, and 
ending four years before the index date (Web Figure 1) (31). This four year lag serves to 
reduce the risk of protopathic bias, as the use of benzodiazepines in this period may be a 
marker of undiagnosed dementia (32).  
 
For all patients, we obtained details of all drugs prescribed before the index date. Our primary 
exposures were the number of defined daily doses (DDDs) prescribed for benzodiazepines 
(World Health Organisation Anatomical Therapeutic Chemical [ATC] category N05BA, 
N05CD, or N03AE) and benzodiazepine related drugs (Z-drugs; ATC N05CF) during the 
DEP. The DDD is the assumed average maintenance dose per day for a drug based on its 
main indication in adults; we used the DDD values assigned by the World Health 
Organisation’s Collaborating Centre for Drug Statistics Methodology.  
 
We defined ‘new users’ of benzodiazepines as those prescribed benzodiazepines during the 
DEP but with no benzodiazepine prescriptions in the 12 months before the DEP, and 
‘prevalent’ benzodiazepine users as those prescribed benzodiazepines within both the DEP 
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and the 12 months prior (Web Figure 1). New and prevalent users of Z-drugs were defined 
similarly. 
 
Covariates 
Potential confounders were identified as any known or suspected risk factors for dementia (3, 
33) or predictors of benzodiazepine initiation (34, 35). Each covariate was ascertained first 
using only the patient record up to the start of the DEP and second using the patient record up 
the end of the DEP. 
 
The following covariates were measured as binary variables reflecting any history of a 
diagnosis: diabetes, diabetes complications, hyperlipidemia/dyslipidaemia, hypertension, 
stroke/transient ischaemic attack, congestive heart disease, heart failure, peripheral arterial 
disease, atrial fibrillation, angina, myocardial infarction, coronary artery operations, deep 
vein thrombosis, depression, urinary incontinence, Parkinson's disease, severe mental illness, 
drug abuse, epilepsy, anxiety, anxiety symptoms, insomnia, fatigue, other sleep problems, 
migraine, headache, back/neck pain, and neuropathic pain.  Depression severity was 
measured as the maximum record in their history (mild, moderate, or severe), and depression 
duration defined as the years since first record of a depression diagnosis or symptom. 
 
The following covariates were measured as recorded in the GP records in both the 12 months 
before the start and the end of the DEP: any fall, any fracture, number of consultations, any 
prescription for a selective serotonin reuptake inhibitor (ATC N06AB), tricyclic 
antidepressant (ATC N06AA), or an antipsychotic (ATC N05A). Smoking status (none, 
former, current), body mass index (<20, 20-24.9, 25-29.9, 30+ kg/m
2
), and harmful alcohol 
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use (>49 units per week for men and >35 units per week for women) were measured 
according to latest record.  
 
Statistical analyses 
We used conditional logistic regression to estimate the association between categorised 
DDDs (0, >0-29, 30-364, 365-1459, or 1460+ DDDs) of benzodiazepines and Z-drugs and 
dementia incidence. Odds ratios (OR) and 95% confidence intervals were estimated 
unadjusted and then separately adjusted for birth year, practice region (Scotland, Northern 
Ireland, Wales and ten health regions of England), and the covariates listed above.  
To test the impact of covariate ascertainment timing we estimated two sets of models, first 
including covariates measured at the start of the DEP, and second including covariates 
measured at the end of the DEP.  We then estimated associations among new users and 
prevalent users compared to non-users in each case.  
 
The impact of each covariate was measured by the change in log-odds ratio induced by 
adding that covariate to a model only including the exposure stratified into new and prevalent 
use (36).  The impact of each covariate was compared when it was measured at the start or 
end of the DEP.  Confidence intervals were calculated by non-parametric bootstrapping. 
 
Finally, to test whether associations between new use and dementia incidence varied with the 
time between medication initiation and dementia incidence, we stratified ORs for any new 
prescription and total DDDs during the DEP by time of initiation in three periods: 15-20, 10-
15, or 5-10 years prior to dementia (among those with at least 16, 11 and 6 years of Up-To-
Standard data history respectively). For these analyses we adjusted for covariates at the later 
of the interval start date and the DEP start date. 
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Throughout, multiple imputation via chained equations was used to impute missing values of 
body mass index, harmful alcohol use and smoking (37) (see Web Appendix for details of 
imputation models). We used Stata version 14.2 for all statistical analysis. Statistical 
significance was determined using two-tailed tests, with a pre-specified threshold of P<0.01.  
 
RESULTS 
Of 66,136 cases of dementia recorded in CPRD between 2006 and 2015, 40,770 met 
inclusion criteria and were matched to 283,933 controls (Web Figure 2). The median 
(interquartile range) drug exposure period was 7.1 (4.0-11.3) years in duration; median age at 
index date was 83 (78-87) years and 63% were female (Table 1).   
 
By definition, the proportion of patients with a history of each clinical condition increased 
over the DEP (Web Table 2).  For example, up to the start of their DEP, 25,870 patients (8%) 
had a diagnosis of anxiety and 21,347 (7%) had insomnia.  By the end of the DEP this had 
increased to 41,788 (13%) and 52,578 (16%) respectively. Cases were more likely than 
controls to have a history of cardiovascular disease and depression, and to visit their GP more 
frequently. 
 
Among the cases, 8,010 (20%) were ever prescribed benzodiazepines and 3,130 (8%) were 
prescribed Z-drugs during their DEP, compared to 52,017 (18%) and 19,163 (7%) of the 
controls respectively. The five most common prescriptions were for Temazepam (32% of all 
benzodiazepine or Z-drug prescriptions), Zopiclone (19%), Diazepam (18%), Nitrazepam 
(14%), and Lorazepam (5%). See Web Table 3 for details of prescribing patterns. 
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Association between benzodiazepine prescriptions and dementia incidence 
The unadjusted OR for dementia and any prescription of a benzodiazepine was 1.09 (95% 
confidence interval [CI]: 1.06, 1.12), but there was little suggestion of a dose-response 
relationship with the number of DDDs (Table 2). Adjusting for covariates measured at the 
start of the DEP, led to an inverse association between benzodiazepines and dementia (OR 
for ≥4 years of DDDs = 0.88, 95% CI: 0.82, 0.95).  When adjusting for covariates measured 
at the end of the DEP the inverse association appeared stronger (OR=0.81 for any use, 95% 
CI: 0.75, 0.87).  
 
New vs prevalent users of benzodiazepines 
Of those prescribed benzodiazepines, 37,303 (62%) patients were new users during the DEP, 
while 22,724 (38%) were prevalent users (Table 2). New users had shorter average exposures 
to benzodiazepines during the DEP than prevalent users who represented most cases of 
‘chronic’ use.  Among new users there was little evidence for an association between 
benzodiazepines and dementia incidence when adjusted for covariates measured at the start of 
the DEP (hence adjusted for factors recorded before medication initiation; OR=1.03, 95% CI: 
1.00, 1.07), but the negative association was still apparent among prevalent users (OR=0.91, 
95% CI: 0.87-0.95), for whom the start of the DEP is after medication initiation. When 
adjusted for covariates measured at the end of the DEP, a negative association was seen for 
both new use (OR=0.91, 95% CI: 0.88-0.95) and prevalent use (OR=0.85, 95% CI: 0.81-
0.89) of benzodiazepines. 
 
Impact of each covariate 
The number of physician consultations, anxiety, insomnia, depression, and antidepressant 
prescriptions each substantially modified the estimated association between benzodiazepine 
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use and dementia incidence when added to the conditional logistic regression models, while 
other factors did not (Web Figure 3 and Web Table 4).  Covariates modified the association 
more when measured at the end of the DEP; patterns were similar for prevalent and incident 
use. 
 
Proximity between exposure and outcome 
New use of benzodiazepines was not significantly associated with an increased risk of 
dementia regardless of whether the first prescription was 5-10, 10-15 or 15-20 years prior to 
dementia (Table 3).  Although estimates are imprecise, associations did appear to increase 
with closer proximity between exposure initiation and outcome. 
 
Z-drug prescriptions and dementia 
Of those prescribed Z-drugs, 18,704 (84%) patients were new users during the DEP, while 
3,589 (16%) patients had received prescriptions during the DEP and additionally in the 
previous 12 months. There was a positive association between Z-drugs and dementia 
incidence without adjusting for covariates.  No association was observed when adjusting for 
covariates measured at the start of the DEP, and evidence of a negative association was 
observed when adjusting for covariates measured after the DEP (Web Tables 5 and 6).  The 
pattern of the impact of individual covariates was almost identical for Z-drugs and 
benzodiazepines, with depression, antidepressant use, physician consultations, anxiety and 
insomnia having the greatest impact on estimated associations (Web Figure 4 and Web Table 
7).  As with benzodiazepines, this impact was up to three or four times greater when 
covariates were measured at the end of the DEP compared to the start of the DEP, and was 
consistent for both prevalent and new users of Z-drugs.   
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DISCUSSION 
Associations between benzodiazepine and Z-drug prescriptions and dementia incidence 
depend on the timing of covariate ascertainment and whether prevalent or only new use is 
considered.  When covariates were only measured before exposure, associations were 
typically null or slightly positive. When covariates were included in the models that may 
have occurred before or after initiation of drug exposure, associations were typically 
negative.  Taken together, our results suggest no causal link between benzodiazepines or Z-
drug use and later dementia incidence, that any positive association is an artefact of either 
inadequate control of confounding factors or protopathic bias, and any negative association is 
the result of adjusting for colliders in regression models. 
 
In every case, adjustment for depression, anxiety, antidepressant use, insomnia, fatigue, and 
number of recent physician visits had the most impact on our estimates.  No other covariate 
substantially affected the relationships in any analysis.  As well as being possible indications 
for benzodiazepines, depression, anxiety and sleep disturbance are known symptoms of 
dementia, and are suspected risk factors (3).  Therefore, there are several equally plausible 
explanations for the observed relationships between these variables in our study.  Figure 1 
illustrates confounding, reverse causation, colliding and mediating relationships.  Panels A 
and B show the importance of controlling for neuropsychiatric symptoms while panels C and 
D illustrate the danger in doing this, since the record of neuropsychiatric symptoms may act 
as a collider or a mediator.  Note that in each case, neuropsychiatric symptoms might equally 
be recorded before or after the measured exposure and so these scenarios cannot be 
definitively distinguished theoretically or empirically. 
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Nevertheless, by varying the timing of covariate ascertainment compared to the timing to 
treatment initiation we can place reasonable bounds on causal associations by considering 
whether each analysis is more likely to under- or over-estimate it.  For new users, the start of 
the DEP might be some time before treatment initiation, and so controlling for covariates 
measured up to this time risks residual confounding and over-estimating associations.  
Covariates measured at the end of the DEP may have occurred post-treatment and so 
including these risks under-estimation. For prevalent users, any measured covariate may have 
occurred post-treatment initiation hence under-estimation is more likely, while univariable 
analyses and those with short lag times are likely to lead to over-estimation. 
 
The key strengths of our study include the detailed evaluation of the impact of varying study 
design parameters and use of an exposure period up to 20 years prior to diagnosis of dementia 
for a significant number of cases. Diagnosis of dementia in CPRD has been validated with a 
positive predictive value of 95% (2). The available data allowed us to carefully consider the 
roles of a wide range of potential covariates measured at different points.  Measurement of 
exposure was based on prescription rather than use, but these are likely to be similar, 
particular for chronic users.  
 
Substantively, our study updates and builds on the findings of Imfeld et al who reported no 
significant association with benzodiazepine or Z-drug use and risk of dementia (18), also 
based on a case-control study nested within CPRD although using a time period for case-
ascertainment that began prior to financial incentives for the accurate recording of dementia 
diagnoses in UK primary care. Gray et al report a small association among low users that was 
not observed when the lag period was extended beyond two years, again suggesting no causal 
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link (17).  A Swiss study also reported no association between benzodiazepine prescriptions 
and new dementia medication prescriptions, despite only allowing a two year lag period (38).  
 
Study design choices might explain previously reported positive associations between 
benzodiazepine use and dementia.  Two studies that did not apply any lag between exposure 
and outcome likely over-estimated the causal effect (14, 16). A study based on a Canadian 
insurance claims database reported a significant association with a dose-response relationship 
(15).  Although they controlled for anxiety and sleep disturbance, they did not have any 
record of these indications for most users, suggesting that control of confounding factors was 
inadequate. 
 
Inclusion of prevalent users in pharmacoepidemiologic studies is challenging.  However, 
previous studies examining benzodiazepine use and dementia incidence report only slightly 
smaller associations with prevalent use compared to new use (14, 39). 
 
In summary we find no evidence that benzodiazepine or Z-drug use is associated with risk of 
dementia. However, as benzodiazepines have known side-effects including falls and sedation 
and lead to tolerance (6), prescribers should to follow guidelines on avoiding or limiting their 
use. 
 
Our study reinforces the challenges in estimating associations between long-term cumulative 
exposures and adverse events with long latent or prodromal periods, particularly where 
indications for the exposure are also prodromal symptoms of the outcome.  Nevertheless, 
these remain important questions that observational studies provide almost the only 
opportunity to answer, and so these challenges must be addressed.  Investigators should 
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carefully consider the causal framework for potential covariates, when measured at different 
time points and among prevalent and new users, and should be mindful that prodromal 
periods for neurodegenerative diseases could be extremely long. Given the inherent difficulty 
of measuring confounders and of separating confounding from mediating or colliding effects 
in these cases, observational studies should not necessarily aim to provide single unbiased 
effect estimates, but can provide robust upper or lower bounds on effect sizes, depending on 
study design, that should be considered alongside other forms of evidence using for example, 
a triangulation framework to narrow the range of plausibly true causal effects (40). 
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Tables  
 
Table 1. Sociodemographics and Data history of Dementia Cases and Controls in the United 
Kingdom, April 2006-July 2015  
 
Dementia Cases 
(n=40,770) 
Controls 
(n=283,933) 
Characteristic No. % No. % 
Women
a
 25,745 63.1 179,152 63.1 
Age at index date, years
ab
 82.6 (6.8) 82.6 (6.8) 
Practice level Index of Multiple 
Deprivation quintile
a
    
1 (least deprived) 7,867 19.3 54,766 19.3 
2 7,928 19.4 55,220 19.4 
3 8,756 21.5 61,032 21.5 
4 8,389 20.6 58,407 20.6 
5 (most deprived) 7,830 19.2 54,508 19.2 
Country 
    
England 30,615 75.1 223,468 78.7 
Northern Ireland 1,508 3.7 8,720 3.1 
Scotland 5,024 12.3 25,793 9.1 
Wales 3,623 8.9 25,952 9.1 
Drug exposure period 
length
ac
, years 
7.1 (4.0-11.3) 7.1 (4.0-11.3) 
 
a 
Matching variables 
b 
Values are expressed as mean (standard deviation) 
c 
Values are expressed as median (interquartile range)  
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Table 2. Association Between Benzodiazepine Prescriptions and Dementia, by Defined Daily 
Doses, New or Prevalent use, and when Covariates are Measured, in a Nested Case-Control 
Study in the UK, December 1988-July 2015 
 
Number of Benzodiazepine No. of  No. of  Unadjusted 
Measured at Start 
of DEP 
Measured at End of 
DEP 
DDDs During DEP Cases Controls OR 95% CI aORa  95% CI aORa  95% CI 
All Users 
        Any benzodiazepine prescription 8010 52017 1.09 b 1.06, 1.12 0.99 0.96, 1.02 0.89 b 0.86, 0.92 
DDDs during DEP 
        0 32760 231916 1.00 Referent 1.00 Referent 1.00 Referent 
0.1-29 3949 25390 1.10 b 1.07, 1.14 1.02 0.99, 1.06 0.92 b 0.89, 0.96 
30-364 1998 12516 1.13b 1.08, 1.19 1.01 0.96, 1.06 0.88 b 0.84, 0.93 
365-1459 1143 7775 1.04 0.98, 1.11 0.92 0.86, 0.98 0.84 b 0.78, 0.89 
≥1460 920 6336 1.03 0.96, 1.11 0.88b 0.82, 0.95 0.81 b 0.75, 0.87 
Users Stratified by New and Prevalent Use 
        Any benzodiazepine prescription during 
DEP 
        0 32760 231916 1.00 Referent 1.00 Referent 1.00 Referent 
Any prescription by new users 5058 32245 1.11 b 1.08, 1.15 1.03 1.00, 1.07 0.91 b 0.88, 0.95 
Any prescription by prevalent users 2952 19772 1.06 b 1.02, 1.10 0.91 b 0.87, 0.95 0.85 b 0.81, 0.89 
DDDs during DEP 
        None 32760 231916 1.00 Referent 1.00 Referent 1.00 Referent 
Within New Users 
           0.1-29 3568 23103 1.10 b 1.06, 1.14 1.02 0.99, 1.07 0.92 b 0.89, 0.96 
   30-364 1135 6987 1.15 b 1.08, 1.23 1.05 0.98, 1.12 0.88 b 0.82, 0.94 
   365-1459 269 1567 1.22 b 1.07, 1.39 1.10 0.96, 1.25 0.94 0.82, 1.07 
   ≥1460 86 588 1.04 0.83, 1.30 0.96 0.76, 1.20 0.84 0.67, 1.05 
Within Prevalent Users 
           0.1-29 381 2287 1.18* 1.06, 1.32 1.00 0.89, 1.12 0.93 0.83, 1.04 
   30-364 863 5529 1.10 b 1.03, 1.19 0.97 0.90, 1.04 0.89 b 0.83, 0.96 
   365-1459 874 6208 1.00 0.93, 1.07 0.87 b 0.81, 0.94 0.81 b 0.75, 0.87 
   ≥1460 834 5748 1.03 0.96, 1.11 0.87 b 0.81, 0.94 0.81 b 0.75, 0.87 
 
Abbreviations: DDD, defined daily doses; DEP, drug exposure period; OR, odds ratio; aOR, 
adjusted odds ratio; CI, confidence interval  
 
a 
Adjusted for: all variables in Table 1 and Web Table 2 
 
b
 p < 0.01 
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Table 3. Association Between New Benzodiazepine Prescriptions and Dementia, According 
to When the New Prescription was Issued, in a Nested Case-Control Study in the UK, 
December 1988-July 2015  
 
Number of No. of  No. of  Unadjusted 
Adjusted for Covariates 
Measured at Start of DEP 
DDDs Cases Controls OR 95% CI aORa 95% CI 
New Use Initiated 15-20 Years Priorb  
Benzodiazepine prescription 
    No 7747 43261 1.00 Referent 1.00 Referent 
Yes 560 2916 1.06 0.97, 1.17 0.98 0.89, 1.08 
DDDs during DEP 
     0 7747 43261 1.00 Referent 1.00 Referent 
0.1-29 283 1646 0.96 0.84, 1.09 0.90 0.79, 1.02 
30-364 201 863 1.27c 1.09, 1.49 1.16 0.99, 1.36 
365-1459 43 232 1.02 0.74, 1.42 0.91 0.65, 1.27 
≥1460 33 175 1.02 0.70, 1.48 0.97 0.66, 1.41 
New Use Initiated 10-15 Years Priord  
Benzodiazepine prescription 
    No 18097 105328 1.00 Referent 1.00 Referent 
Yes 1316 6741 1.12 c 1.05, 1.19 1.01 0.95, 1.08 
DDDs during DEP 
     0 18097 105328 1.00 Referent 1.00 Referent 
0.1-29 849 4304 1.14 c 1.05, 1.22 1.03 0.95, 1.11 
30-364 322 1756 1.05 0.93, 1.18 0.93 0.82, 1.05 
365-1459 107 464 1.32 1.06, 1.63 1.17 0.95, 1.45 
≥1460 38 217 0.99 0.70, 1.40 0.92 0.65, 1.30 
New Use Initiated 5-10 Years Priore  
Benzodiazepine prescription 
    No 31471 191614 1.00 Referent 1.00 Referent 
Yes 2564 13636 1.14 c 1.09, 1.19 1.03 0.99, 1.08 
DDDs during DEP 
     0 31471 191614 1.00 Referent 1.00 Referent 
0.1-29 1904 10289 1.12 c 1.07, 1.18 1.03 0.98, 1.08 
30-364 528 2707 1.18 c 1.08, 1.30 1.04 0.94, 1.14 
365-1459 117 568 1.23 1.01, 1.50 1.08 0.88, 1.32 
≥1460 15 72 1.26 0.72, 2.20 1.16 0.66, 2.02 
 
Abbreviations: DDD, defined daily doses; DEP, drug exposure period; OR, odds ratio; aOR, 
adjusted odds ratio; CI, confidence interval  
 
a 
Adjusted for all variables in Table 1 and Web Table 2 
b
 Including patients with ≥16 years of Up-To-Standard data history before the index date 
c
 p < 0.01 
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d Including patients with ≥11 years of Up-To-Standard data history before the index date. 
Start of period defined by the later of the start of the DEP and 15 years prior to the index 
date. 
e Including patients with ≥6 years of Up-To-Standard data history before the index date. Start 
of period defined by the later of the start of the DEP and 10 years prior to the index date 
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Figure legend 
 
 
Figure 1.  Directed acyclic graphs in a nested case-control study in the UK, December 1988-
July 2015, illustrating theoretically plausible relationships between psychiatric conditions, 
benzodiazepine prescription (exposure), neurodegenerative disease, and the record of 
psychiatric symptoms (measured covariate that might be caused by a primary 
neuropsychiatric condition or a latent neurodegenerative disease) and dementia diagnosis 
(outcome).  Solid outlines indicate observed variables.   Dashed lines indicate false 
associations induced by omitted variable bias (panel A representing confounding by 
indication and panel B representing reverse causation) or adjusting for a collider (panel C).   
Panel D shows that in the case of a genuine relationship between benzodiazepines and 
dementia, ‘record of neuropsychiatric symptoms’ following treatment initiation may reflect a 
mediator of the relationship. 
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